- •As both teriflunomide and IFN β are similar in terms of effectiveness in the treatment of patients with RRMS, evaluation of safety profile can help the clinician to choose the most appropriate therapy.
- •All MS medications target the immune system and therefore have the theoretical potential to predispose patients to infection, to reduce surveillance of neoplasms, or to induce autoimmune disease, among other potential adverse effects.
- •Liver toxicity might be a reason for discontinuation of any drug prescribed, as it could potentially be a life-threating complication.
- •Elevated ALT is an indication of liver impairment particularly in acute cases, as drug-related liver failure, and is preferred over AST, as the former is more liver-specific while the latter is also produced by other tissues and can be increased in extrahepatic diseases.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- 1New approaches to the diagnosis, clinical course, and goals of therapy in multiple sclerosis and related disorders.Continuum (Minneap Minn). 2016; 22: 723-729
- 2Disease-modifying treatments for multiple sclerosis - a review of approved medications.Eur. J. Neurol. 2016; 23: 18-27
- 3Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.Ther. Adv. Neurol. Disord. 2015; 8: 212-232
- 4Disease modifying therapies for relapsing multiple sclerosis.BMJ. 2016; 354: i3518
- 5The transition from first-line to second-line therapy in multiple sclerosis.Curr. Treat. Options Neurol. 2015; 17: 354
- 61b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.Neurology. 1993; 43: 655-661
- 71b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group.Neurology. 1995; 45: 1277-1285
- 8(Prevention of relapses and disability by interferon beta-1a suncutaneously in multiple sclerosis) study group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis.Lancet. 1998; 352: 1498-1504
- 9Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).Lancet (London, England). 2002; 359: 1453-1460
- 10Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.Lancet Neurol. 2014; 13: 657-665
- 11Liver injury associated with the beta-interferons for MS: a comparison between the three products.Neurology. 2004; 62: 628-631
- 12Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.Drug Saf. 2003; 26: 815-827
- 13Randomized trial of oral teriflunomide for relapsing multiple sclerosis. Chill maz (HB, PT) — both fr stock (TPO).Sanofi-Aventis N. Engl. J. Med. 2011; 14365: 1293-1303
- 14Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol. 2014; 13: 247-256
- 15Annex I - Teriflunomide summary of product characteristics.Eur. Med. Agency. 2009; ([Accessed July 14, 2017]): 1-16
- 16The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.Ann. Intern. Med. 2015; 162: 777-784
- 17Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 402-415
- 18Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.Lancet. 2012; 380: 1819-1828
- 19Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.N Engl J Med. 2008; 359: 1786-1801
- 20Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.Lancet. 2012; 380: 1829-1839
- 21Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.J. Neurol. Sci. 2012; 312: 97-101
- 22Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis.N Engl J Med. 2015; 373: 1418-1428
- 23Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the rebif vs glatiramer acetate in relapsing ms disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.Lancet Neurol. 2008; 7: 903-914
- 24250 ??G or 500 ??G interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.Lancet Neurol. 2009; 8: 889-897
- 25Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.Mult. Scler. J. 2014; 20: 705-716
- 26Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.Mult. Scler. J. 2012; 18: 1278-1289
- 27Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 μg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study.Clin. Ther. 2008; 30: 1102-1112
- 28Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.BMC Neurol. 2012; 12: 154
- 29Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology. 1993; 43: 655-661
- 30Evaluation of abnormal liver tests.Med. Clin. North Am. 2014; 98: 1-16